tiprankstipranks
Trending News
More News >

Synaptogenix Restructures Leadership Amid Strategic Refocus

Story Highlights
Synaptogenix Restructures Leadership Amid Strategic Refocus

Confident Investing Starts Here:

An announcement from Synaptogenix ( (SNPX) ) is now available.

Synaptogenix has extended the employment term of its CEO, Dr. Alan J. Tuchman, with a reduced salary and entered a new consulting agreement with its President, Dr. Daniel L. Alkon, also with a reduced fee. The company is focusing on strategic opportunities to enhance investor value, supported by $19.6 million in cash reserves. Synaptogenix is exploring partnerships and non-dilutive investments for its Bryostatin-1 asset, while also reducing its cash burn rate by terminating a Phase 1 trial due to slow enrollment.

More about Synaptogenix

Synaptogenix is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases. Its lead therapeutic candidate, Bryostatin-1, has been studied in Alzheimer’s disease and other conditions such as Fragile X syndrome and multiple sclerosis. The company benefits from Orphan Drug Designation for Bryostatin-1 in treating Fragile X syndrome.

YTD Price Performance: -62.28%

Average Trading Volume: 20,633

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $3.48M

For detailed information about SNPX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1